July 10, 2019
Roche/Chugai Pharmaceutical’s hemophilia A treatment Hemlibra (emicizumab) demonstrated sustained safety and efficacy in patients with and without factor VIII inhibitors, according to long-term follow-up data from four PIIII HAVEN studies. Across the four studies, which altogether covered 400 patients of...read more